The key contents of the official instructions of Mavakatai (Mafantuo) and the precautions for taking the medicine

1. Overview of Drugs

Mavacamten (trade name: Mavacamten) is an oral myocardial contraction inhibitor and a new type of selective cardiac myosin inhibitor. It is mainly used to treat symptomatic hypertrophic cardiomyopathy (HCM), especially patients with left ventricular outflow tract obstruction. The drug reduces the force of over-contracted myocardium by regulating the activity of cardiac contractile proteins, thereby reducing the left ventricular outflow tract pressure gradient, improving cardiac pumping function, and alleviating symptoms such as angina, dyspnea, decreased exercise tolerance, and fatigue.

Mavacate's unique mechanism of action distinguishes it from traditional heart medications, such asbeta blockers, calcium channel blockers or diuretics. It fundamentally improves the hemodynamic abnormalities of hypertrophic cardiomyopathy by acting directly on cardiac contractile proteins rather than by regulating the nervous or vascular system.

2. Indications and contraindications

1.According to the official instructions, Mavakatai is suitable for:

Adult patients with symptomatic hypertrophic cardiomyopathy, especially with left ventricular outflow tract obstruction.

Patients with fair cardiac function and no severe heart failure or severely reduced left ventricular ejection fraction.

2.Taboo groups include:

Patients who are allergic to Mavaceta or any excipients.

Patients with severe heart failure or significantly reduced left ventricular ejection fraction.

Pregnant women, lactating women and patients with potential risks to the fetus should avoid use.

Additionally, there are insufficient data on use in children, so it should be used with caution or only under strict medical supervision by children and adolescent patients.

3. Dosage and usage

The official instructions emphasize that Mavaceta should be taken orally once a day, and the dose needs to be individually adjusted based on the patient's weight, left ventricular ejection fraction and left ventricular outflow tract pressure gradient. The general treatment plan is as follows:

1. Starting dose: The doctor will select the initial dose based on the patient’s heart ultrasound and weight, usually starting with a lower dose.

2.Dose adjustment: Evaluate the efficacy and safety through regular follow-up of left ventricular ejection fraction (LVEF) and left ventricular outflow tract pressure gradient (LVOT), and the dose can be gradually increased or decreased if necessary.

3.Taking time: It is recommended to take the medicine orally at a fixed time. It can be taken with a meal or on an empty stomach, but it should be taken at the same time every day to ensure stable blood concentration.

If you miss a dose, take it as soon as possible that day, but avoid taking a double dose at once.

4. Monitoring and precautions during medication

1.Heart function monitoring

Mavacartide may cause a decrease in left ventricular ejection fraction or worsening of heart failure symptoms. During treatment, cardiac ultrasound examination must be performed regularly to monitor LVEF and LVOT pressure gradients. If LVEF drops to the warning range or symptoms of heart failure occur, the dose needs to be suspended or adjusted.

2.Drug interactions

Mavaceta is mainly metabolized by the liverCYP2C19 and CYP3A4. The combined use of strong inducers or inhibitors of these enzymes may affect blood concentration. Examples: antifungals, certain antibiotics, and antiepileptic drugs. Patients should inform their doctors about all prescription drugs, over-the-counter drugs and health supplements while taking them.

3.Adverse reactions and treatment

Common adverse reactions include dizziness, fatigue, palpitations, hypotension, edema and transient heart failure symptoms. Mild symptoms can be relieved with monitoring and lifestyle adjustments; if symptoms are severe or persistent, contact your doctor immediately.

4.Lifestyle coordination

Patients should maintain a regular schedule, exercise moderately, and avoid strenuous physical activity or excessive stress. A healthy diet and adequate fluid intake can help reduce the burden on your heart.

5. Special Populations and Medication Safety

1.Pregnant and lactating women

Mavaceta may have potential risks to the fetus, so its use should be avoided during pregnancy; lactating women should weigh the pros and cons under the guidance of a doctor.

2.Elderly patients

Elderly patients may have lower tolerance to drugs and should start at low doses under the guidance of a doctor and monitor cardiac function regularly.

3.Patients with abnormal liver function

Moderate to severe abnormalities in liver function may lead to an increase in blood drug concentration and increase the risk of cardiac adverse reactions. It should be used with caution and closely monitored.

6. Summary

MavacamtenMavacamten), as a targeted therapeutic drug for hypertrophic cardiomyopathy, improves left ventricular outflow tract obstruction and cardiac pumping function by directly regulating cardiac contractile protein activity. The official instructions emphasize individualized dosage, regular monitoring of cardiac function, and attention to drug interactions. During the period of taking the medicine, patients need to follow the doctor's advice, regularly review cardiac indicators, pay attention to adverse reactions and deal with them in a timely manner, and at the same time cooperate with a healthy lifestyle. Through scientific management and standardized medication, Mavakatai can significantly improve patient symptoms, exercise endurance and quality of life while ensuring safety.

Reference link:https://www.drugs.com